rheumatoid arthritis

View All

Potential of Cannabidiol (CBD) as a Treatment Substance
Can Cannabinoids be an Effective Medicinal Substance?

Cannabidiol (CBD) is one of the 120 cannabinoids present naturally in cannabis plants. After tetrahydrocannabinol (THC), Cannabidiol is the second most prevalently available cannabinoid. Cannabidiol, an important component of medicinal marijuana, is either directly from the hemp plant or synthesized in a laboratory...

Find More

pharma-news-for-merck-pfizer-gilead-abbvie-lantern-polpharma
Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

Merck’s Chronic Cough Med Gefapixant Receives A Red Flag From the FDA, Requests For More Data On 24th January 2022, Merck & Co. announced FDA rejection for its New Drug Application (NDA) of Gefapixant (experimental drug) for unexplained or chronic cough. FDA asked for additional information on the drug, rela...

Find More

Rheumatoid arthritis market | Rheumatoid arthritis treatment market | Rheumatoid arthritis market | Rheumatoid arthritis drug pipeline
Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market

The past decade experienced a lot of shuffling in the Rheumatoid arthritis (RA) market. The journey started with the approvals of disease-modifying anti-rheumatic drugs (DMARDs). Several conventional DMARDs constituting methotrexate, leflunomide, hydroxychloroquine, and sulfasalazine, biologics with initial entrant...

Find More

Rheumatoid arthritis treatment market
The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach

Beyond the shadow of a doubt, the Rheumatoid arthritis (RA) treatment market has witnessed strides of improvements during the last few years. There was a time when the treatment for RA was confined to Non-steroidal anti-inflammatory drugs (NSAIDs) and steroids, which could only address pain and swelling. However, t...

Find More

pharma-news-updates-for-biomarin-gilead-alzheon
FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

FDA rejects BioMarin's gene therapy and Gilead's filgotinib over concerns The FDA refused to approve BioMarin's hemophilia A gene therapy valoctocogene roxaparvovec. The U.S. regulator that had earlier told there was no requirement of an AdComm for the drug, aka, valrox, has issued a complete response (CRL) lett...

Find More

Latest COVID News | Pharma Happenings
HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results

The US FDA nullified the Emergency Use Authorization (EUA) granted to chloroquine phosphate and hydroxychloroquine sulfate to treat COVID-19. The regulatory authority had granted the EUA to malarial drugs to be used in hospitalized COVID-19 patients only when a clinical trial was unavailable, or participation in...

Find More

covid-news
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit

Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients.  The company plans to explore the anti-inflammatory responses that were witnessed in rheumatoid arthritis patients, and how the drug – Olumiant – an oral JAK1/JAK2 inhibitor – might help in cur...

Find More

Bioelectronic Medicine
Bioelectronic Medicine: Applications and Future Prospects

Healthcare industry during the past few decades has witnessed phenomenal growth and improvement due to technological advancement and innovation. The hospital management, medical devices & equipment, pharmaceutical products, and surgical procedures all have gone under tremendous up-gradation and improvement.&nbs...

Find More

Pharma News
Moderna’s COVID-19 vaccine; AcelRx buys TetraPhase; Breakthrough designation to Baricitinib

Moderna announces dozing of first patient with its mRNA1273 vaccine The pharmaceutical company, Moderna, has been developing a vaccine for the treatment of COVID-19. The vaccine is an mRNA-1273 is developed by scientist at NAID, in collaboration with Moderna, and the manufacturing of the vaccine for Phase I clin...

Find More

Pharma News
JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC)  The drug has been recommended for its use in NSCLC patients with epidermal growth factor (EGFR) Exon 20 insertion mutations, categorized wit...

Find More